Immunic
IMUX
44 hedge funds and large institutions have $125M invested in Immunic in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 6 reducing their positions, and 4 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
22% more capital invested
Capital invested by funds: $102M → $125M (+$22.8M)
10% more funds holding
Funds holding: 40 → 44 (+4)
95% less call options, than puts
Call options by funds: $108K | Put options by funds: $2.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.89M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.35M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$2.85M |
| 4 |
DA
DSC Advisors
Chicago,
Illinois
|
+$1.03M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$781K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.04M |
| 2 |
Goldman Sachs
New York
|
-$1.1M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$723K |
| 4 |
Citigroup
New York
|
-$597K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$443K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | – | – |
|
IMUX Hedge Fund Activity: Q1 2015 in Review
44 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q1 2015, worth a combined $125M — up 22% from $102M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IMUX positions and 4 closed out — a net gain of 4 holders — while 20 added to existing stakes and 6 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $9.89M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.04M sold.
- 44 institutional investors held Immunic (IMUX) as of Q1 2015, up from 40 in Q4 2014.
- Funds reported $125M of Immunic stock for Q1 2015, up 22% quarter-over-quarter.
- 8 funds opened new Immunic positions in Q1 2015 and 4 closed out, a net change of +4 holders.
- The largest Immunic buyer in Q1 2015 was T. Rowe Price Associates, an estimated $9.89M added.
- The largest Immunic seller in Q1 2015 was Sphera Funds Management, an estimated $2.04M sold.
Based on aggregated 13F filings for Q1 2015.